Koers Synaptogenix, Inc. Other OTC
Aandelen
SNPX
US87167T1025
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 5,54 mln. 5,15 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -5 mln. -4,65 mln. | Nettowinst (verlies) 2023 | -6 mln. -5,58 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 37,48 mln. 34,84 mln. | Nettoliquiditeiten 2023 | 30,1 mln. 27,98 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,42
x | K/w-verhouding 2023 |
-0,23
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 97,57% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01-01-18 |
Daniel Alkon
PSD | President | 81 | 07-12-20 |
Robert Weinstein
DFI | Director of Finance/CFO | 64 | 01-06-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01-01-18 |
Bruce Bernstein
BRD | Director/Board Member | 60 | 14-11-16 |
Joshua Silverman
CHM | Chairman | 53 | 04-08-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+22,81% | 46,81 mld. | |
+47,02% | 41,29 mld. | |
-1,88% | 41,37 mld. | |
-6,20% | 28,87 mld. | |
+11,33% | 26,06 mld. | |
-21,00% | 19,13 mld. | |
-1,43% | 11,96 mld. | |
+30,73% | 12,39 mld. | |
-0,48% | 12,08 mld. |